This study was designed to investigate the expression of four actin-binding proteins, a-actinin-4, cofilin 1, fascin and elongation factor 1-a 2 (eEF1A2), in samples of breast cancer from 112 patients with different stages of breast cancer (stages T0 -T1, T2 and T3) compared with normal control tissues (n = 33). Levels of eEF1A2 and aactinin-4 mRNA appeared to be unrelated to tumour size, except for a significant down-regulation of a-actinin-4 mRNA in T3 cases. Significant up-regulation of cofilin 1 mRNA was associated with stages T0 -T1 and T2; up-regulation seen at stage T3 was not significant compared with control tissue. Fascin mRNA levels were significantly reduced at all three tumour stages (T0 -T1, T2 and T3) compared with control tissue. In conclusion, some components of the actin cytoskeletal system might hold significant potential as targets in future cancer therapies.
Introduction
Actin-binding proteins (ABPs) bind to actin and may have the ability to bind to actin monomers or polymers, or to both. 1, 2 Many ABPs, including α-actinin, β-spectrin, dystrophin, utrophin and fimbrin, do this through the actin-binding calponin homology domain. 3 Although most previous research on ABPs has focused on the regulation of cytoskeletal organization, the effect of ABP expression on tumour metastasis has also attracted attention, largely due to the results of certain clinical trials. 4 -6 In almost all cases, tumours that are highly malignant tend to have downregulated ABP and this down-regulation is often responsible for a change in actin formation. 7 Actin can control the motility of cells 8 and it also participates in many important cellular processes, including muscle contraction, cell division and cytokinesis, vesicle and organelle movement, cell signalling, and the establishment and maintenance of cell functions and cell shape. 9 Previous research has suggested that cell motility needs a balance between actin monomer and polymer formation rather than only the assembly of actin polymers. 8, 10 This finding does not, however, agree with the down-regulation of ABP observed in all previous clinical studies of tumour cells, 11 since over-expression might lead to over-Y Zhang, X Tong Actin-binding proteins and breast tumour size assembly of actin and, therefore, to the prevention of tumour cell motility and cancer metastasis.
Metastasis of breast cancer is a serious clinical problem. According to the American Joint Committee on Cancer (AJCC) 6th Staging Manual, 12 the tumour, node, metastasis (TNM) staging of breast cancer is based on tumour size, and the presence of lymph node and distant metastases. This staging scheme is highly indicative of breast cancer prognosis. In previous studies that have attempted to investigate the relationship between the presence of cancer metastasis and ABP status, researchers have mainly focused on lymph node status because enrolment of enough cases with distant metastases is problematic. 10, 13 Recently, evidence has suggested that the biological function of some ABPs is not as simple as first imagined, 14 and research into the role played by ABPs in cancer metastasis is urgently required. There are many different types of protein that can bind directly or indirectly to actin, however, the present study limited itself to the investigation of four ABPs: α-actinin-4 (encoded by the ACTN4 gene), cofilin 1 (encoded by the CFL1 gene), fascin (encoded by the FSCN1 gene), and elongation factor 1-α 2 (eEF1A2; encoded by the EEF1A2 gene), as these proteins seem to play a role in the motility and metastases of cancer cells. The aim of the present study was to explore the pattern of expression of these four ABPs, by measuring relative mRNA levels in breast tumour samples from patients with different stages of disease.
Patients and methods

PATIENTS AND TISSUE SAMPLES
Tumour tissues were obtained from patients who had undergone mastectomy or lumpectomy at Tongji University and Tongji Hospital (Shanghai, China) and at Fudan University and Shanghai Tumour Hospital (Shanghai, China) between 2002 and 2008, with complete follow-up of discharged patients between 2002 and 2004 and incomplete follow-up after 2004. Additionally, samples of normal breast tissue were obtained as a control from women who were diagnosed with fibroadenoma; the tissue was taken from the area surrounding the fibroadenoma. Tumour staging was based on the AJCC 6th Staging Manual. 12 Samples of both tumour and normal tissue were stored in liquid nitrogen.
Ethical approval was obtained from the Institutional Review Boards of Tongji University and Fudan University. Written informed consent was obtained from all participants of the study.
RNA EXTRACTION AND CDNA SYNTHESIS
Total cellular RNA was extracted from tumour and normal tissue samples by using TRIzol ® reagent (Invitrogen, Carlsbad, CA, USA) strictly according to the manufacturer's instructions. All Eppendorf tubes and pipette tips were DNase-and RNase-free in order to prevent RNA degradation. The extracted RNA was dissolved in distilled water treated with diethyl pyrocarbonate and the RNA solution was stored at -80°C. The total RNA concentration was quantified spectrophotometrically by measuring the optical density at 260 nm (OD 260 ) and purity was measured from the OD 260 /OD 280 ratio. First-strand cDNA synthesis was performed using 2 µg RNA with random hexamers and 300 U Moloney Murine Leukaemia Virus (M-MLV) reverse transcriptase (Promega, Madison, WI, USA) for 60 min at 37°C.
REAL-TIME POLYMERASE CHAIN REACTION
To amplify the mRNA encoding the four ABP Y Zhang, X Tong Actin-binding proteins and breast tumour size proteins, specific primer sets (sense and antisense) were designed using the National Center for Biotechnology Information's (NCBI's) Primer-BLAST (Basic Local Alignment Search) tool (National Institutes of Health, Bethesda, MD, USA). The primer sequences are given in Table 1 . Preliminary experiments showed that mRNA levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were extremely stable in the experimental samples and this housekeeping gene was, therefore, chosen to standardize the quantitative experiments. Real-time polymerase chain reaction (PCR) was set up using iQ™ SYBR ® Green Supermix (Toyobo Co. Ltd, Osaka, Japan) and the iQ™5 real-time PCR detection system (Bio-Rad, Hercules, CA, USA) according to the manufacturers' instructions. The thermal cycling conditions included a pre-denaturation step for 1 min at 95°C and 40 cycles of a three-step procedure, including a 15-s denaturation step at 95°C, a 15-s annealing step at 56°C, and a 45-s extension step at 72°C. Amplification specificity was assessed by melting curve analysis. The cycle threshold (CT) values obtained by real-time PCR were quantified using a relative standard curve. For this purpose, eight dilutions (obtained by two-fold serial dilution) of a pool of cDNAs were quantified. Results were expressed as the target/internal standard (GAPDH) concentration ratio of the sample divided by the target/internal standard concentration ratio of the calibrator. Each experiment was repeated at least three times to assess reproducibility.
STATISTICAL ANALYSIS
Quantitative data are expressed as mean ± SE for each experimental group. Statistical analyses were performed using the SPSS ® statistical package, version 13.0 (SPSS Inc., 
5′-GATGACGCCTACGGCCACCG-3′OH
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CFL1, cofilin 1; ACTN4, α-actinin-4; FSCN1, fascin; EEF1A2, elongation factor 1-α2; NCBI, National Center for Biotechnology Information.
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Chicago, IL, USA) for Windows ® . Analyses of the data were performed using one-or twoway analysis of variance with Dunnett's or Bonferroni's post-hoc comparison tests. A Pvalue < 0.05 was considered to be statistically significant.
Results
Samples from 112 female breast cancer patients treated from 2002 to 2008 were analysed: 47 patients were TNM stage T0 -T1 (mean age 48.4 years; range 18 -85 years); 34 patients were TNM stage T2 (mean age 46.7 years; range 17 -88 years); and 31 patients were TNM stage T3 (mean age 48.6 years; range 29 -81 years). Normal tissues from 33 women diagnosed with fibroadenoma, taken from the area surrounding the fibroadenoma were included as a control (mean age 46.5 years; range 16 -82 years). None of patients had received neo-adjuvant therapy, nor had previously received hormone therapy. All samples were primary tumours without a previous history of breast cancer.
Mean levels of cofilin 1 mRNA in the stage T0 -T1, T2 and T3 groups were approximately 4-, 4.5-and 1.5-times higher than that of the normal control group, respectively (Fig. 1A) . The differences were statistically significant for the stage T0 -T1 and T2 groups versus controls (P < 0.05 and P < 0.01, respectively).
Mean levels of fascin mRNA in the stage T0 -T1, T2 and T3 groups were approximately 1/5, 1/4 and 1/6 of that of the normal control group, respectively (Fig. 1B) . All of the differences were statistically significant (P < 0.01).
Mean levels of eEF1A2 mRNA in the different samples showed no statistically significant differences between in the four groups (Fig. 1C) and, for α-actinin-4 mRNA, only the stage T3 group showed significantly lower levels than the control group ( Fig. 1D ; P < 0.05).
Discussion
Actin-binding proteins are usually thought of as being part of the cell motility machinery within the cell. From this point of view, it would be reasonable to suggest that aberrant ABP expression could be involved in cell invasion. The expression of ACTN4, CFL1, FSCN1 and EEF1A2 has been investigated in various clinical studies, three of which have suggested that ABPs could affect cell invasion by actin bundling. 4 -6 According to this theory, ABP could exist in this same mode in cancer cells, although our research does not support this idea.
There are six kinds of actin in the actin family and these proteins have been highly conserved during evolution. 2 Undoubtedly, β-actin is the most important member of the actin family as it is widespread, existing in almost all tissues, and it provides the main cytoskeletal network of the cell. 15 There is limited research interest in the other five isoforms of actin.
Cancer cells exploit defects in the normal cellular regulatory circuits. Tumour cell migration and adhesion and tumour cell interactions with host extracellular matrix and with host cells are important features during the switch to the metastatic state. 16 The actin cytoskeleton is a central player in these processes and, as a consequence, it is involved in many aspects of cancer development and progression. 17 The present study appears to be in agreement with this and suggests that cell mobility may play an important role in the development of breast cancer.
From a logic perspective, both actin itself and members of the large group of ABPs may be affected in the cancer cell. The differential functioning of the actin system might be based on: (i) the presence of Y Zhang, X Tong Actin-binding proteins and breast tumour size mutant proteins (actin isoforms, ABPs); (ii) altered expression levels of their genes; and/or (iii) altered activation status of these genes and proteins as a consequence of altered upstream signalling.
Many genes, such as those for ablinteractor 1 (Ab-1), LIM and SH3 protein 1 (LASP1), tropomyosin 3 (TPM3), moesin (MSN) and neurofibromin 2 (NF2), that encode ABPs have frequently been observed to display genetic defects in cancer cells suggesting a causal contribution of these genes to oncogenesis or malignant tumour progression. 18 -20 A cancer gene is assigned as such if it carries at least one germ-line mutation and/or more than five unambiguous somatic mutations in at least two independently analysed primary tumours. 21 Intriguingly, all of the ABP genes listed above (Ab-1, LASP1, TPM3, MSN and  NF2) bind filamentous actin and, in a number of cases, the fusion protein retains Factin-binding capacity. 22 To date, there has been limited research on the impact of Out of the four proteins that were investigated in the present study, expression of the FSCN1 gene demonstrated the most significant changes in terms of mRNA levels in tumour versus control tissue, and these were similar to previously published research. 23 Reduced expression of the FSCN1 gene appeared to be associated with progression from the benign to the malignant state. Fascin organizes filamentous actin into bundles with a minimum of a 4.1:1 actin/fascin ratio, which means that over-expression of the FSCN1 gene inhibits cell motility. 24 Thus, the downregulation of fascin observed in the present study would appear to agree with what is known about the role of fascin in cell motility. A potential contradiction to this was the finding of higher expression of the FSCN1 gene in TNM stage 2 versus the T0 -T1 and T3 samples, although this difference was not statistically significant.
Tomlinson et al. 25 have studied EEF1A2 gene expression and their results suggest that this translation elongation factor is an oncoprotein in breast cancer. In contrast, eEF1A2 mRNA levels were not significantly different in tumour versus control breast tissue in the present study, which might be due to the two studies using different ways to quantify EEF1A2 gene expression.
Expression of the CFL1 gene has rarely been examined in clinical studies 6 and ACTN4 gene expression has only been investigated from a prognostic point of view. 26 With respect to CFL1 and ACTN4 gene expression, we believe that the present study is the first to measure mRNA levels of these genes in breast cancer at different stages of tumour progression, based on tumour size (T stage). Unexpected results were observed for these two ABPs. The biological function of the cofilin 1 protein is to disassemble actin filaments. 27 Thus, it could be expected that all breast cancer samples might express higher levels of cofilin 1 mRNA than normal tissue. Although cofilin 1 mRNA was significantly increased in stages T0 -T1 and T2, there was only a slight increase (not statistically significant) at stage T3 versus control tissues. Human α-actinin-4 is encoded by the ACTN4 gene and the protein belongs to the spectrin gene superfamily, which represents a diverse groups of cytoskeletal proteins, including spectrin and dystrophins. 26 Levels of ACTN4 mRNA were only significantly down-regulated at stage T3 in the present study, suggesting that ACTN4 is down-regulated in larger tumours.
In conclusion, the present study suggested that ABPs were involved to some extent in tumour progression but, as yet, there is not a complete understanding of their individual roles at the molecular level. The data suggest, however, that components of the actin cytoskeletal system might hold significant potential as targets in future cancer therapies.
